ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $34,955 | -8.8% | 970,151 | 0.0% | 1.76% | +3.2% |
| Q4 2022 | $38,340 | -99.9% | 970,151 | 0.0% | 1.70% | -7.8% |
| Q3 2022 | $38,981,000 | -4.4% | 970,151 | 0.0% | 1.85% | +5.1% |
| Q2 2022 | $40,785,000 | +7.9% | 970,151 | 0.0% | 1.76% | +8.5% |
| Q1 2022 | $37,797,000 | -2.2% | 970,151 | 0.0% | 1.62% | -5.3% |
| Q4 2021 | $38,661,000 | +10.3% | 970,151 | 0.0% | 1.71% | +3.7% |
| Q3 2021 | $35,061,000 | -11.8% | 970,151 | 0.0% | 1.65% | -9.7% |
| Q2 2021 | $39,766,000 | -99.1% | 970,151 | 0.0% | 1.83% | -91.5% |
| Q1 2021 | $4,231,798,000 | +113.6% | 970,151 | -75.5% | 21.59% | -0.4% |
| Q4 2020 | $1,981,228,000 | +18.5% | 3,958,498 | -0.4% | 21.69% | +8.2% |
| Q3 2020 | $1,671,777,000 | -13.3% | 3,973,800 | 0.0% | 20.05% | -28.5% |
| Q2 2020 | $1,929,279,000 | – | 3,973,800 | – | 28.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |